VTRS — Viatris Inc.

Viatris (VTRS) Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics:

• Total revenues reached $3.5 billion, a 3% increase from Q1 2025.
• Adjusted EBITDA was $1 billion, reflecting a 10% growth year-over-year.
• Adjusted EPS stood at $0.59 per share.
• Free cash flow generated was $348 million, with an adjusted figure of approximately $459 million when excluding one-time costs.
• Adjusted gross margin remained stable at 56%.

2. Strategic Updates and Business Highlights:

• Viatris is focusing on three strategic imperatives: driving the base business, fueling an innovative portfolio, and modernizing for sustainable growth.
• Significant growth was noted in Greater China (18% year-over-year), driven by cardiovascular product demand and e-commerce investments.
• The company launched EFFEXOR for generalized anxiety disorder in Japan and anticipates further product launches, including XULANE LO and fast-acting meloxicam.
• Progress in the pipeline includes regulatory approvals for several products and ongoing Phase III studies for selatogrel and cenerimod.
• A disciplined approach to capital allocation continues, with $140 million returned to shareholders through dividends.

3. Forward Guidance and Outlook:

• The company reaffirmed its financial guidance for 2026, expecting stronger growth in Greater China and maintaining a positive outlook despite potential headwinds.
• Total revenues, adjusted EBITDA, and adjusted EPS are expected to be weighted towards the second half of the year due to product seasonality and launch timing.
• Viatris anticipates that foreign currency exchange rates may provide a 1% tailwind on revenues and adjusted EBITDA.

4. Bad News, Challenges, or Points of Concern:

• Emerging markets saw flat net sales, which was below expectations, primarily due to supply constraints in the lower-margin ARV portfolio.
• European net sales declined by approximately 1%, attributed to competitive pressures and supply constraints.
• There are ongoing risks related to policy changes in China and potential impacts from increased competition in the generics market.
• The company faces challenges from supply constraints affecting its ARV business, although mitigation efforts are underway.

5. Notable Q&A Insights:

• Management expressed confidence in the durability of growth in China, attributing it to strong execution and investments in e-commerce.
• The strategic focus remains on in-market accretive assets, with less emphasis on early-stage R&D investments for the time being.
• Questions regarding the selatogrel trial design highlighted the complexity of the endpoint assessment, with management clarifying the ranking system for patient outcomes.
• The specialty sales force for fast-acting meloxicam is expected to consist of 150-200 reps, focusing on outpatient settings and postoperative pain management.
• Management indicated that the company is on track to achieve $120 million in cost savings as part of its strategic review, with expectations for continued operating leverage into future years.

Overall, Viatris reported a strong start to 2026, with solid revenue growth and a focus on strategic initiatives, while also navigating challenges in certain markets and product segments.